Bioventix delivered a strong set of interims, with revenues up 25% to £5.9m, adjusted EBITDA +24% to £4.7m and adjusted pre-tax profit up 26% to £4.6m. Due to a weaker GBP, translation of overseas revenues boosted revenues by c.9% (c.£0.4m), implying a still strong 16% CER growth rate. In line with its policy of maintaining c.£5m cash on the balance sheet, an interim dividend of 62p was declared (+19%), with net cash at period end of £5.15m. Revenue growth was well balanced, with troponin revenu ....

27 Mar 2023
Bioventix - Interims – a strong start to the year underpins FY forecast
Bioventix Plc (BVXP:LON) | 3,715 0 0.0% | Mkt Cap: 193.9m
-
-
-
Mark Brewer | Team Legacy Research
-
14 pages
-

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bioventix - Interims – a strong start to the year underpins FY forecast
Bioventix Plc (BVXP:LON) | 3,715 0 0.0% | Mkt Cap: 193.9m
- Published:
27 Mar 2023 -
Author:
Mark Brewer | Team Legacy Research -
Pages:
14 -
Bioventix delivered a strong set of interims, with revenues up 25% to £5.9m, adjusted EBITDA +24% to £4.7m and adjusted pre-tax profit up 26% to £4.6m. Due to a weaker GBP, translation of overseas revenues boosted revenues by c.9% (c.£0.4m), implying a still strong 16% CER growth rate. In line with its policy of maintaining c.£5m cash on the balance sheet, an interim dividend of 62p was declared (+19%), with net cash at period end of £5.15m. Revenue growth was well balanced, with troponin revenu ....